To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer (VERU-100)

• ClinicalTrials.gov Identifier: NCT04843319
• Recruitment Status: Active, not recruiting
• First Posted: April 13, 2021
• Last Update Posted: January 12, 2022
• Sponsor: Veru Inc.
• Information provided by (Responsible Party): Veru Inc.

Study Description

Brief Summary:

To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.

Condition or disease	Intervention/treatment	Phase
Advanced Prostate Adenocarcinoma	Drug: VERU-100	Phase 1; Phase 2

Detailed Description:

This study is a multicenter, randomized, open-label, dose finding study of VERU-100 to attain and maintain serum total testosterone levels within castrate range (<50ng/dL) in men with advanced prostate cancer. Stage 1 of the study will assess the effect of VERU-100 at various doses. Stage 2 will further assess the efficacy of the effective doses of VERU-100 in an expanded patient population.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 40 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: Open label single arm
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
• Actual Study Start Date: June 9, 2021
• Estimated Primary Completion Date: February 28, 2022
• Estimated Study Completion Date: March 30, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: VERU-100 at various doses; 150 mg, 200 mg, 300 mg or 400 mg of VERU-100	Drug: VERU-100; GnRH antagonist

Outcome Measures

Primary Outcome Measures :

1. Percent of men with total testosterone at <50 ng/dL by day 28 [ Time Frame: Day 28 ]
   Percent of men that reach castrate level (<50 ng/dL) of total testosterone levels by Day 28

Secondary Outcome Measures :

1. Total testosterone below 20ng/dL levels on VERU-100 [ Time Frame: Day 28 and Day 91 ]
   Percent of men that reach <20 ng/dL of total testosterone levels by Day 28 that are maintained at <20 ng/dL through Day 91

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 100 Years (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Gender Based Eligibility: Yes
• Gender Eligibility Description: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Be over 18 years of age
• Be able to communicate effectively with the study personnel
• Have histologically confirmed prostate cancer
• Have prostate cancer staged T3-4NxMx or TxN1Mx or TxNxM1 according to the TNM classification or the patient should have rising PSA after failed local therapy and be candidate for androgen deprivation therapy
• Have a QTc interval <440 ms
• Subjects are judged by the attending physician and/or Principal Investigator to be a candidate for androgen deprivation therapy (continuous therapy)
• ECOG performance status of 0 to 2
• Baseline morning serum testosterone levels >150 ng/dL at Screening Visit
• Have a life expectancy of ≥18 months

• Subjects must agree to use acceptable methods of contraception

  1. If their female partners are pregnant or lactating, acceptable methods of contraception from the time of the first administration of study medication until 6months following administration of the last dose of study medication must be used. Acceptable methods are: Condom used with spermicidal foam/gel/film/cream/suppository. If the subject has undergone surgical sterilization (vasectomy with documentation of azoospermia),a condom with spermicidal foam/gel/film/cream/suppository should be used.
  2. If the male subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 6 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/cream/suppository [i.e.,barrier method of contraception], surgical sterilization (vasectomy with documentation of azoospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam/gel/film/cream/suppository).
  3. If the female partner has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used.
  4. If the female partner has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS),a barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used.

• Laboratory values within the following ranges: hemoglobin ≥10 gm/dL, total bilirubin

  • 1.5x upper limit of normal (ULN), AST ≤2.5x ULN, ALT ≤2.5x ULN,
  • 1.5 mg/dL, absolute neutrophil count ≥1500 cell/uL and platelets ≥100,000 cells/uL.
• Creatinine clearance ≥60 mL/min based on Cockcroft-Gault equation.
• Subject is willing to comply with the requirements of the protocol through the end of the study

Exclusion Criteria:

• Prior androgen deprivation therapy within 6 months prior to Screening Visit.
• Potentially curable disease receiving ADT for localized disease
• History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
• Received chemotherapy, cryotherapy, or antiandrogen therapy within 8 weeks prior to the Screening visit for the treatment of prostate cancer.
• Known hypersensitivity to cetrorelix or other LHRH antagonists
• History of Torsade de Pointes
• Currently taking QT-prolonging drugs
• Any disease or condition (medical or surgical) which might compromise the hematologic, cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk
• Use of exogenous testosterone within 6 months of Screening Visit
• Use of 5α-reductase inhibitor within 3 months of Screening Visit
• Use of systemic corticosteroids at a dose >10 mg/day at Screening
• Major surgery within 4 weeks of Screening Visit (including surgery for prostate cancer)
• Uncontrolled symptomatic congestive heart failure (NYHA Class III -IV), unstable angina pectoris, cardiac arrhythmia, or uncontrolled atrial fibrillation
• History of diabetes mellitus Type 1. Uncontrolled diabetes mellitus Type 2 (control with oral hypoglycemic agents are allowed)
• Received an investigational drug within a period of 90days prior to enrollment in the study
• Received the study medication (VERU-100) previously
• Have been previously diagnosed or treated for active cancer(other than prostate cancer or non-melanoma skin cancer) within the previous five years

Contacts and Locations

Locations

United States, Arizona

Arizona Urology Specialist

Tucson, Arizona, United States, 85704

Urology Associates of Southern Arizona

Tucson, Arizona, United States, 85715

United States, Arkansas

Arkansas Urology

Little Rock, Arkansas, United States, 72211

United States, California

San Bernardino Urological Associates

San Bernardino, California, United States, 92404

United States, Indiana

First Urology, PSC

Jeffersonville, Indiana, United States, 47130

United States, Maryland

Chesapeake Urology Research Associates

Towson, Maryland, United States, 21204

United States, New York

Associated Medical Professionals of NY, PLCC

Syracuse, New York, United States, 13210

United States, North Carolina

Associated Urologists of North Carolina

Raleigh, North Carolina, United States, 27612

United States, Ohio

Clinical Research Solutions

Middleburg Heights, Ohio, United States, 44130

United States, Pennsylvania

MidLantic Urology

Bala-Cynwyd, Pennsylvania, United States, 19004

United States, South Carolina

Carolina Urologic Research Center

Myrtle Beach, South Carolina, United States, 29572

United States, Texas

Houston Metro Urology

Houston, Texas, United States, 77027

Urology San Antonio

San Antonio, Texas, United States, 78229

United States, Virginia

Urology of Virginia

Virginia Beach, Virginia, United States, 23462

Sponsors and Collaborators

Veru Inc.

Investigators

• Study Chair: Bernette; Veru Inc.

More Information

• Responsible Party: Veru Inc.
• ClinicalTrials.gov Identifier: NCT04843319
• Other Study ID Numbers: V2010001
• First Posted: April 13, 2021
• Last Update Posted: January 12, 2022
• Last Verified: January 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Adenocarcinoma; Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type